BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Esophageal Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Esophageal Cancer\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06907602-1973@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT06907602)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Esophageal Squamous Cell Carcinoma.
 \nStudy: Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Es
 ophageal Squamous Cell Carcinoma\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 07602
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1973@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, G
 lioblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion
 : 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06047379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1974@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gliob
 lastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06047379
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2009@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Sa
 fety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Glio
 blastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 2
 8 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipil
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06047379
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07531979-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07531979)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Prospective\, Open-label\, Multi-cohort Study of Becotatug Vedotin W
 ith Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - 
 Phase 2\nEstimated primary completion: 31 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07531979
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751055-2009@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07751055)
DESCRIPTION:Ipilimumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nStu
 dy: Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody
  Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer\nEst
 imated primary completion: 1 April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07751055
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265285-1974@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06265285)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Compa
 rison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab
  Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls 
 (CCBW) Program\nEstimated primary completion: 1 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265285
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06354140-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06354140)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC
  After Radical Resection With Neoadjuvant STUDY\nEstimated primary complet
 ion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tis
 lelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06354140
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319730-1973@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05319730)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Esophageal Squamous Cell Carcinoma.
 \nStudy: A Study to Evaluate Investigational Agents With or Without Pembro
 lizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previous
 ly Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Deat
 h Ligand 1 (PD-L1) Treatment (MK-3475-06B)\nEstimated primary completion: 
 11 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05319730
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405151-2527@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270612
DTEND;VALUE=DATE:20270613
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT07405151)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Esophageal Squamous Cell Ca
 rcinoma.\nStudy: A Clinical Trial of Ifinatamab Deruxtecan in People With 
 Advanced Esophageal Cancer (MK-3475-06F)\nEstimated primary completion: 12
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifinatama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07405151
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07046221-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07046221)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Tislelizumab Combined With Chemotherapy for Resectable Esophageal Sq
 uamous Cell Carcinoma Followed by CRT or Surgery\nEstimated primary comple
 tion: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07046221
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152678-1974@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07152678)
DESCRIPTION:Nivolumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nStud
 y: Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in 
 Esophageal Squamous Cell Carcinoma\nEstimated primary completion: Septembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0715267
 8
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764355-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06764355)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Sur
 gery for Advanced Esophageal Squamous Cell Carcinoma\nEstimated primary co
 mpletion: December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06764355
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07721103-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07721103)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Early Response-guided Sequential Radiotherapy After Chemoimmunothera
 py for Locally Advanced Esophageal Squamous Cell Carcinoma\nEstimated prim
 ary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07721103
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811752-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07811752)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Sacituzumab Govitecan Combined With Tislelizumab for Locally Advance
 d/Metastatic Esophageal Cancer\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078117
 52
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678580-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07678580)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemothe
 rapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma\nE
 stimated primary completion: 31 January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07678580
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747585-1973@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06747585)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pe
 mbrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors\nEstimated
  primary completion: 15 February 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06747585
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747585-2338@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:ALE.P02: Phase 1/2 readout est. (NCT06747585)
DESCRIPTION:ALE.P02\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Investigate ALE.P02 as a Monotherapy or in Combination With Pembroli
 zumab in Adult Patients With Selected CLDN1+ Solid Tumors\nEstimated prima
 ry completion: 15 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ale-p02#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06747585
URL:https://assetmemo.bio/drug/ale-p02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733180-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07733180)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: A Study Investigating Alternate Schedules of Tislelizumab Plus Chemo
 therapy in Japanese Patients With First-line Advanced ESCC\nEstimated prim
 ary completion: 28 February 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07733180
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487896-2817@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tambotatug pelitecan: Phase 3 readout est. (NCT07487896)
DESCRIPTION:Tambotatug pelitecan\, phase 3\, Esophageal Squamous Cell Carci
 noma.\nStudy: A Study of YL201 Versus Investigator's Choice of Chemotherap
 y in Participants With Locally Advanced or Metastatic Esophageal Squamous 
 Cell Carcinoma After Failure of First-Line Therapy\nEstimated primary comp
 letion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tambotatug-pelitecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07487896
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644781-2527@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Ifinatamab Deruxtecan: Phase 3 readout est. (NCT06644781)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 3\, Esophageal Squamous Cell Carc
 inoma.\nStudy: A Study of Ifinatamab Deruxtecan in Subjects With Pretreate
 d Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate
 -Esophageal01)\nEstimated primary completion: 1 June 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06644781
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686926-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07686926)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Adva
 nced Esophageal Squamous Cell Carcinoma\, Phase II\nEstimated primary comp
 letion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07686926
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128693-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07128693)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: A Single-center\, Multicohort\, Phase II Clinical Study Evaluating t
 he Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresec
 table\, Locally Advanced\, Recurrent\, or Metastatic Esophageal Squamous C
 ell Carcinoma\nEstimated primary completion: December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07128693
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554456-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 2/3 readout est. (NCT07554456)
DESCRIPTION:Tislelizumab\, phase 2/3\, Esophageal Squamous Cell Carcinoma.\
 nStudy: A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluoroura
 cil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Tre
 atment in Patients With Unresectable\, Locally Advanced Recurrent or Metas
 tatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07554456
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554456-2044@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07554456)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Esophageal Squamous Cell 
 Carcinoma.\nStudy: A Study of BL-B01D1 in Combination With Tislelizumab ±
 5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as Fir
 st-line Treatment in Patients With Unresectable\, Locally Advanced Recurre
 nt or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07554456
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07039162-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07039162)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Study of Tislelizumab Combined With Chemoradiotherapy and Surgery fo
 r Unresectable Esophageal Squamous Cell Carcinoma\nEstimated primary compl
 etion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07039162
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700667-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07700667)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: SKB500 Combinations in Patients With Esophageal Squamous Cell Carcin
 oma\nEstimated primary completion: 31 December 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07700667
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205731-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07205731)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Phase II Study Evaluating Safety and Efficacy of Tislelizumab for El
 derly Patients Unfit for Chemotherapy\, With Advanced Esophageal Squamous-
 cell Carcinoma\nEstimated primary completion: October 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07205731
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621601-2501@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07621601)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Esophageal Squamous Cell Carci
 noma.\nStudy: A Study of HS-20093 in Patients With Pretreated Advanced or 
 Metastatic Esophageal Squamous Cell Carcinoma (ESCC)\nEstimated primary co
 mpletion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/risvutatug-rezetecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07621601
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914011-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20310628
DTEND;VALUE=DATE:20310629
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06914011)
DESCRIPTION:Tislelizumab\, phase 3\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Res
 ected Locally Advanced Esophageal Squamous Cell Carcinoma\nEstimated prima
 ry completion: 28 June 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06914011
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006650-1973@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06006650)
DESCRIPTION:Pembrolizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\n
 Study: Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous
  Cell\nEstimated primary completion: 31 December 2031. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06006650
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554521-2010@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07554521)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemoth
 erapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroeso
 phageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial an
 d Ethnic Minority Patients in the United States\nEstimated primary complet
 ion: 31 December 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07554521
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780111-1973@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20320104
DTEND;VALUE=DATE:20320105
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06780111)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Esophageal Squamous Cell Carcinoma.
 \nStudy: Substudy 06E: Umbrella Study of Combination Therapies in Esophage
 al Cancer (MK-3475-06E/KEYMAKER-U06)\nEstimated primary completion: 4 Janu
 ary 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6780111
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780111-2527@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20320104
DTEND;VALUE=DATE:20320105
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06780111)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Esophageal Squamous Cell Ca
 rcinoma.\nStudy: Substudy 06E: Umbrella Study of Combination Therapies in 
 Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)\nEstimated primary completion
 : 4 January 2032. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifi
 natamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06780111
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
